8-KLeadership Changes

STRYKER CORP 8-K Report, Executive Changes (Aug 3, 2009)

Filed August 3, 2009For Securities:SYK

Summary

Stryker Corporation (SYK) announced a change in its board composition through a Form 8-K filed on August 3, 2009. The key event reported is the appointment of Srikant M. Datar to the Company's Board of Directors on July 29, 2009. Dr. Datar also joined the Audit Committee, indicating a focus on financial oversight. His appointment includes standard compensation for non-employee directors and a stock option grant, aligning his interests with shareholders. Dr. Datar brings significant academic and corporate experience to Stryker, holding a professorship at Harvard University and directorships in other prominent companies. This addition to the board suggests a commitment by Stryker to leverage external expertise in governance and strategic direction. Investors should note that this filing primarily addresses a board appointment and related compensation, rather than financial performance or operational updates.

Key Highlights

  • 1Srikant M. Datar appointed to Stryker Corporation's Board of Directors on July 29, 2009.
  • 2Dr. Datar also appointed to serve on the Board's Audit Committee.
  • 3Dr. Datar was granted an option to purchase 13,330 shares of Common Stock at an exercise price of $39 per share.
  • 4Dr. Datar will receive a pro-rated portion of the $115,000 annual fixed fee for non-employee directors.
  • 5Dr. Datar possesses extensive academic credentials, including a professorship at Harvard University.
  • 6Dr. Datar serves on the boards of other public companies: Novartis AG, ICF International, Inc., and KPIT Cummins Infosystems Limited.
  • 7The filing indicates Stryker is strengthening its board with experienced professionals in financial oversight and corporate governance.

Frequently Asked Questions

Srikant M. Datar is a Senior Associate Dean and Professor at Harvard University's Graduate School of Business Administration. His appointment to the Stryker Board of Directors and its Audit Committee likely aims to enhance the company's corporate governance and financial oversight with his extensive academic and consulting experience.

Dr. Datar was granted an option to purchase 13,330 shares of Stryker common stock at $39 per share. He will also receive a pro-rated amount of the $115,000 annual fixed fee paid to non-employee directors.

No, this Form 8-K filing specifically reports on a change in the board of directors and related compensation. It does not contain any information regarding Stryker's financial performance, revenues, or earnings.

His appointment to the Audit Committee is significant as it suggests a strengthened focus on financial reporting integrity, risk management, and internal controls. The Audit Committee plays a crucial role in overseeing these areas on behalf of the Board and shareholders.